Bacteriophage therapy--cooked goose or phoenix rising?

Area of Science:

• Microbiology
• Biotechnology
• Pharmacology

Background:

• Bacteriophage therapy is emerging as a viable alternative to antibiotics for treating bacterial infections.
• Recent studies in animals and humans indicate potential for both internal and external applications.
• The regulatory landscape for phage therapy is evolving with increasing clinical evidence.

Purpose of the Study:

• To review the current status and future prospects of bacteriophage therapy.
• To highlight key considerations for the clinical and regulatory validation of phage-based treatments.
• To emphasize the importance of defining the 'active substance' for optimal therapeutic outcomes.

Main Methods:

• Review of recent animal and human clinical trials.
• Analysis of regulatory requirements for Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP).
• Discussion of economic factors and production challenges.

Main Results:

• Bacteriophage therapy has demonstrated potential in alleviating bacterial diseases.
• Regulatory pathways are becoming clearer, necessitating robust GLP studies for safety and clinical trials for efficacy.
• GMP production will be crucial, with anticipated costs comparable to conventional antibiotics.

Conclusions:

• Successful implementation of bacteriophage therapy hinges on clear regulatory pathways and validated safety and efficacy.
• Anticipating GMP production costs similar to antibiotics is essential for market viability.
• Defining the 'active substance' is critical to harness the full potential of bacteriophage diversity and evolution for therapeutic benefit.